Does Wegovy really work for weight loss — and what does the evidence actually show?

Step 1: what semaglutide actually does in your body

Wegovy contains semaglutide, a GLP-1 receptor agonist. GLP-1 is a hormone your gut releases after eating; it signals fullness to your brain, slows the speed at which food leaves your stomach, and damps down appetite between meals. Semaglutide mimics and prolongs those signals. The practical result for most people is that they feel full sooner, stay full longer, and find that the mental pull of food (the craving rather than hunger) quietens noticeably.

That mechanism is well-established. The NHS medicines page for semaglutide describes the same pathway in plain terms for patients. It isn't a metabolism booster or a fat-burner in the colloquial sense; it's a regulator of the signals that drive how much you eat. Understanding that distinction matters for managing expectations.

Treatment starts at 0.25mg weekly and is titrated upward by your prescriber, typically over several months, reaching 2.4mg as the standard maintenance dose. The higher 7.2mg dose was approved by the MHRA in 2026 for adults with a BMI of 30 or above, with trials reporting around 20.7% average weight loss over 72 weeks at that level. Your prescriber decides the pace of any increase.

Step 2: what the trial data genuinely shows

The STEP 1 trial randomised 1,961 adults with obesity or overweight plus a weight-related condition (but without type 2 diabetes) to semaglutide 2.4mg or placebo over 68 weeks. The semaglutide group lost an average of roughly 15% of starting body weight; the placebo group lost about 2.4%. That's a real, clinically significant gap, and it's the foundation of NICE's recommendation for Wegovy.

A few honest caveats are worth spelling out. The trial population followed structured lifestyle support alongside the medicine. Around 7% of participants in semaglutide groups discontinued due to side effects in STEP trials, mostly gastrointestinal. And weight regain after stopping is well-documented: a follow-up study found most of the lost weight returned within a year of discontinuing. Wegovy manages a chronic condition; it isn't a short course that resolves it permanently. If you want a closer look at how well Wegovy performs across different groups, that detail is covered separately.

For context on how quickly people start to notice a difference, the timeline from dose to visible results is explored on the page about when you actually start losing weight on Wegovy.

Step 3: the factors that make results better or worse for real people

Clinical averages hide a wide spread. Some people on 2.4mg lose 5%; others lose more than 20%. Several things seem to shape where you land.

Consistency of dosing matters a great deal. Missing injections regularly, or pausing treatment for weeks at a time, blunts the effect. If you're timing a course around, say, a summer holiday or payday cycles, it's worth discussing that with your prescriber rather than improvising gaps, because the dose schedule isn't forgiving of long breaks.

Diet quality alongside treatment still matters. Semaglutide reduces appetite; it doesn't make poor food choices irrelevant. Protein adequacy in particular helps preserve muscle during weight loss. Strength-based activity alongside treatment is recommended in clinical guidelines.

The dose you reach is also relevant. People who tolerate escalation to the full maintenance dose tend to lose more than those who plateau at a lower dose due to side effects. How quickly Wegovy starts working is a related question many people ask at the same stage.

For a broader look at what semaglutide is and how it's used in the UK, our semaglutide overview covers the licensed context in full.

Side effects: the part that most affects whether it works for you

GI side effects (nausea, loose stools, constipation, burping, reflux) are common, particularly after dose increases. For most people they settle within a week or two at a new dose. A smaller number find them persistent enough to limit titration or prompt stopping altogether.

Serious but uncommon effects include acute pancreatitis: severe stomach pain that radiates to the back, with or without vomiting, needs urgent medical assessment. The MHRA issued a Drug Safety Update in January 2026 reminding prescribers and patients of this risk across GLP-1 medicines. Any suspected side effects can be reported through the Yellow Card scheme.

Wegovy is not recommended during pregnancy, breastfeeding, or while actively trying to conceive, and if you have recently given birth our page on Wegovy postpartum covers the specific guidance for that situation. It isn't licensed for under-18s. A full list of contraindications and drug interactions is in the Patient Information Leaflet supplied with your treatment.

Questions about Wegovy's cost in a private setting are common at this stage too, and if you're still weighing up whether the medicine is likely to be effective for you, our page exploring whether Wegovy really works goes into that in more depth. Our page on weight-loss treatment options sets out what a clinically supervised private course includes. If you'd like to speak to our prescribers directly about whether Wegovy is appropriate for your situation, a free consultation is the place to start.